<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074642</url>
  </required_header>
  <id_info>
    <org_study_id>19-AOI-06</org_study_id>
    <nct_id>NCT04074642</nct_id>
  </id_info>
  <brief_title>OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.</brief_title>
  <acronym>FIRST</acronym>
  <official_title>OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess accurancy of OCT angiography as a pronostic marker for
      patients undergoing neurosurgery for compressiver macroadenoma as compared with visual
      acuity, visual field and OCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of middle deviation</measure>
    <time_frame>before surgery (= inclusion), 4 months after surgery and 10 months after surgery</time_frame>
    <description>visual field evolution assessed by Middle deviation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of visual function index</measure>
    <time_frame>before surgery (= inclusion), 4 months after surgery and 10 months after surgery</time_frame>
    <description>visual field evolution assessed by visual function index</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pituitary Adenoma</condition>
  <arm_group>
    <arm_group_label>Non compressive adenoma</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Optical Coherence Tomography Angiography without surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compressive adenoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optical Coherence Tomography Angiography before and after neurosurgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neurosurgery</intervention_name>
    <description>adenoma removal</description>
    <arm_group_label>Compressive adenoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pituitary compressive adenoma (for experimental group)

          -  pituitary non compressive adenoma

        Exclusion Criteria:

          -  retinian disease

          -  amblyopia

          -  parkinson disease

          -  pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ARNAUD MARTEL</last_name>
    <role>Principal Investigator</role>
    <affiliation>ophtalmology department, Nice University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ARNAUD MARTEL</last_name>
    <phone>0492033737</phone>
    <email>martel.a@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de NICE</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud MARTEL, M.D.</last_name>
      <email>martel.a@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud MARTEL, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Pasteur 2 - Service d'Ophtalmologie</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud MARTEL, MD</last_name>
      <email>martel.a@chu-nice.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>macroadenoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

